SLC5A2 and chronic kidney disease: Among patients with CKD, treatment discontinuation was less commonly observed in the SGLT-2 inhibitor arm compared with the placebo arm: RR 0.88 (95% CI 0.82–0.95; P = 0.001) (Supplemental Fig. 6 and Table 3).